• Publications
  • Influence
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
TLDR
In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. Expand
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
TLDR
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer. Expand
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
TLDR
Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life. Expand
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
TLDR
Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. Expand
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
TLDR
Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer and was associated with a significant survival advantage without the addition of substantial toxicity. Expand
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
TLDR
The addition of cetuximab to FOLFIRI as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. Expand
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated
TLDR
This study demonstrated that panitumumab-FOLFOX4 was well tolerated and significantly improved PFS in patients with WT KRAS tumors and underscores the importance of KRAS testing for patients with mCRC. Expand
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised
TLDR
The combination of ramucirumab with pac litaxel significantly increases overall survival compared with placebo plus paclitaxel, and could be regarded as a new standard second-line treatment for patients with advanced gastric cancer. Expand
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
TLDR
The ECF regimen results in a survival and response advantage, tolerable toxicity, better QL and cost-effectiveness compared with FAMTX chemotherapy, and should now be considered the standard treatment for advanced esophagogastric cancer. Expand
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
TLDR
Although the overall presentation was indeed most consistent with diffuse myocardial injury, it was still necessary to definitively rule out an acute coronary process in this young pregnant woman with abrupt-onset heart failure, prompting coronary angiography after appropriate medical stabilization. Expand
...
1
2
3
4
5
...